European Pharmaceutical Review

AUGUST 14, 2023

Eli Lilly and Company has completed acquisition of two biopharmaceutical companies – Versanis Bio and Sigilon Therapeutics – and their lead assets focused on obesity and diabetes. Lilly announced the successful completion of its acquisition of clinical-stage Versanis Bio and its lead asset bimagrumab, an anti-obesity medicine.

Biopharma 98

Biopharma Leads Medicine Management 98

European Pharmaceutical Review

SEPTEMBER 4, 2023

The biopharma company will be required to seek prior approval before acquiring related products. Divest to invest: the new normal in biopharma? The post FTC order could ease biopharma competition appeared first on European Pharmaceutical Review. The FTC has settled on a proposed consent order with Amgen Inc.

Competition 98

Competition Biopharma Pharmaceutical Government 98

European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted.

Biopharma 98

Biopharma Pharmaceutical Medicine Manufacturing 98

European Pharmaceutical Review

AUGUST 21, 2023

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 trillion in the Q1 of 2023 to $3.56 trillion in Q2 2023.

Biopharma 98

Biopharma Marketing Sales Medicine 98

Pharmaceutical Commerce

APRIL 1, 2024

In this Pharmaceutical Commerce video interview, Barry Heavey, Life Sciences Supply Chain Lead, Accenture, discusses what innovative digital solutions and disruptive technologies he sees transforming the landscape of biopharma manufacturing in the future.

Biopharma 52

Biopharma Manufacturing Leads Pharmaceutical 52

Fierce Pharma

JUNE 7, 2023

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA).

Biopharma 324

Biopharma Leads 324

Pharmaceutical Commerce

APRIL 21, 2023

In this latest Harvard Business School Healthcare Alumni Association Q&A, Dr. Peter Cappelli, Professor of Management at The Wharton School and Director of Wharton’s Center for Human Resources, explains how biopharma C-suites can lead their teams through 2023’s turbulent times.

Biopharma 52

Biopharma Healthcare Healthcare Management 52

Pharmaceutical Commerce

MARCH 29, 2024

In this Pharmaceutical Commerce video interview, Barry Heavey, Life Sciences Supply Chain Lead, Accenture, discusses the specific factors contributing to rising manufacturing costs.

Manufacturing 104

Manufacturing Biopharma Leads Pharmaceutical 104

European Pharmaceutical Review

JULY 29, 2024

In Biopharma, where precision and accuracy are important, integrating robust processes is not just a necessity but a strategic imperative. Overreliance on automation can lead to complacency and blind trust in technology, leading to potential oversight of critical errors or deviations.

Biopharma 52

Biopharma Manufacturing Ethics Competition 52

Pharmaceutical Technology

OCTOBER 31, 2023

Leading biopharmas are reshaping their strategies after the announcement regarding the first drugs subject to Medicare price negotiations under the Inflation Reduction Act (IRA).

Biopharma 52

Biopharma Marketing Leads 52

MedCity News

OCTOBER 29, 2024

Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million.

Biopharma 111

Biopharma Leads Pharma 111

Pharmaceutical Technology

SEPTEMBER 2, 2022

With the takeover, Novo Nordisk will also acquire etavopivat, a lead development candidate of Forma. We have the ambition to build a leading portfolio with standalone and combination treatments to tackle the complications and underlying causes of sickle cell disease.”.

Biopharma 105

Biopharma Leads Patients Pharmaceutical 105

Pharmaceutical Technology

MAY 10, 2023

Swedish Orphan Biovitrum (Sobi) has entered into a definitive agreement to buy biopharmaceutical company CTI BioPharma in an all-cash deal valued at $1.7bn. Sobi will start a tender offer through its wholly owned indirect subsidiary to buy all outstanding CTI shares for $9.10 for each share of common stock in cash.

Biopharma 59

Biopharma Food and Drug Administration Food Medicine 59

MedCity News

SEPTEMBER 9, 2024

The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.

Leads 111

Leads Pharma Pharmaceutical Medical 111

Pharmaceutical Technology

JUNE 2, 2023

Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease. Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material.

Biopharma 52

Biopharma Manufacturing Leads Pharmaceutical 52

European Pharmaceutical Review

AUGUST 24, 2023

This strategy shift did not occur overnight, but evolved in response to the changing biopharma landscape. Even among the leaders of the biopharma sector, few companies have a significant presence across these platforms, Baral highlighted. The post Divest to invest: the new normal in biopharma?

Biopharma 98

Biopharma Pharmaceutical Pharma Medical 98

Pharmaceutical Technology

MAY 15, 2023

Zhejiang DTRM Biopharma and Oncore Biopharma stand in second and third positions, respectively. Exelixis is a biopharmaceutical company that focuses on the development and commercialisation of small molecules for the treatment of cancer. By means of geographic reach, Cytokinetics holds the top position.

Leads 92

Leads Biopharma Pharmaceutical Pharma 92

MedCity News

AUGUST 4, 2022

billion acquisition of Array Biopharma in 2019. Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4

Biopharma 117

Biopharma Leads Pharma 117

MedCity News

APRIL 30, 2024

Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer appeared first on MedCity News. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies. The post J.P.

Leads 123

Leads Safety Biopharma Pharma 123

MedCity News

MAY 6, 2024

Novo-Catalent Deal, Leading to Another Delay appeared first on MedCity News. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process. The post FTC Seeks More Information on the $16.5B

Leads 116

Leads Management Biopharma Pharma 116

MedCity News

MARCH 25, 2024

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.

Biopharma 118

Biopharma Leads Pharma 118

Pharmaceutical Technology

OCTOBER 31, 2024

The company has axed 80% of its staff and is considering a wind-down after the out-licencing deal of its lead antifungal was terminated.

Biopharma 52

Biopharma Leads 52

Pharmaceutical Commerce

SEPTEMBER 6, 2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

Distribution 52

Distribution Biopharma Leads Healthcare 52

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And of course, all of this will feed into future treatments and positive patient outcomes – the sole purpose of pharma.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

Pharmaceutical Technology

JANUARY 20, 2023

Nevertheless, the potential for mAb therapies in treating medical conditions that have limited options means that biopharma companies are investing considerable resources in development. The post Overcoming challenges with scalability in biopharma manufacturing appeared first on Pharmaceutical Technology. Download to learn more.

Biopharma 52

Biopharma Manufacturing Specialization Engineering 52

MedCity News

DECEMBER 5, 2023

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Leads 112

Leads FDA Biopharma Pharma 112

MedCity News

NOVEMBER 14, 2023

Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”

Leads 108

Leads Pharma Pharmaceutical Patients 108

PM360

OCTOBER 8, 2024

A serial entrepreneur, executive business leader and board member, he brings more than 35 years’ experience of critical safety service and technology solution provision to biopharma R&D, Commercial and Operations functions. It was a great honor to be approached to lead Qinecsa’s next important growth phase.

Leads 52

Leads Safety Biopharma Management 52

pharmaphorum

DECEMBER 18, 2022

Uniquely positioned, traditional patient access hubs promise to simplify the process of getting patients started on therapy and offer to provide HCPs with much-needed assistance in navigating payer requirements leading up to therapy starts. However, the cumbersome hub workflow overshadows the purported gains in productivity.

Biopharma 92

Biopharma Patients Prescription Medical 92

Pharmaceutical Technology

MARCH 14, 2023

The company’s lead asset is NBTXR3, which is based on hafnium oxide nanoparticle that is designed to destroy tumors when activated by radiotherapy. The company is involved in designing and manufacturing nanoparticles that safely enhance radiation therapy's efficacy in cancer treatment.

Leads 72

Leads Biopharma Pharmaceutical Manufacturing 72

Pharmaceutical Technology

AUGUST 31, 2022

This higher level of interdependence is due to the rapid growth rate of technology development within the biopharma and pharmaceutical industries. The post Protecting the supply chain: Why biopharma needs integrated workflows appeared first on Pharmaceutical Technology.

Biopharma 52

Biopharma Manufacturing Pharmaceutical Marketing 52

MedCity News

NOVEMBER 27, 2022

The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.

Leads 112

Leads Biopharma Pharma 112

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

MedCity News

JANUARY 9, 2023

billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. AstraZeneca has committed $1.3 In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.

Leads 113

Leads Pharma Biopharma 113

Pharmaceutical Technology

JUNE 4, 2023

Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders. The company’s drug ETX-101, comprising a recombinant adeno-associated virus (AAV9) vector, is under development for the treatment of Dravet syndrome.

Pharmaceutical 105

Pharmaceutical Leads Biopharma Engineering 105

European Pharmaceutical Review

MAY 12, 2023

Swedish Orphan Biovitrum AB (Sobi ® ) has agreed to acquire CTI BioPharma for $1.7 The biopharma companies anticipate the transaction will help to change the treatment landscape for patients with rare diseases through new, innovative and effective medicines and therapies.

Food and Drug Administration 105

Food and Drug Administration Biopharma Medicine Food 105

PharmExec

MARCH 6, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Biopharma 52

Biopharma Leads Manufacturing 52